Medicinal Chemistry &
Drug Discovery Consultancy
Partnering for confidential, well‑advised small‑molecule discovery
Medicinal chemistry strategy & drug hunting
AI‑integrated & structure‑based design
CRO Partnership Building & External Discovery Operations
Early CMC & Fit‑for‑Purpose Batch Delivery
Scientific advisory & due diligence
In Short
Dr Michaël Deligny is a drug hunter with 15+ years of experience in small‑molecule discovery across pharma, biotech, and CRO environments. He contributed to clinical candidates such as the TNFa inhibitor Balinatunfib (SAR441566) at UCB Pharma, now in Phase 2 with Sanofi, and EOS301984, an ENT1 inhibitor in Phase 1.
He has strong expertise in CRO integration, implementing efficient, data‑driven DMTA workflows. His skills include medicinal chemistry strategy, hit‑to‑lead and lead optimisation, SBDD, cheminformatics, and AI‑supported design, with experience across transporters, enzymes, GPCRs, and PPIs.
